Science
Myeloma Paper of the Day, September 11th, Suggested by Robert Orlowski

Myeloma Paper of the Day, September 11th, Suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day:

Ixazomib/Pom/dex regimen for TCE shows ORR of 58% (22% VGPR or better); TCR patients had 46% ORR vs. 68% for non-TCR; median PFS 8.1 (95% CI 3.9-12.3) months and median overall survival was 30.4 (95% CI 21.5-39.4) months.”

Title: Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients – a phase II study

Authors: Tamir Shragai, Noa Lavi, Iuliana Vaxman, Moshe E. Gatt, Evgeni Chubar, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Svetlana Trestman, Eyal Lebel, Revital Saban, Vladimir Vainstein, Tsila Zuckerman, Netanel Horowitz, Inna Tzoran, Nurit Horesh, Noa Lowenton-Spier, Natan Melamed, Ilana Pereg, Irit Avivi, Yael C. Cohen

You can read the full article on Haematologica.

Myeloma Paper of the Day, September 11th, Suggested by Robert Orlowski

You can find other articles featuring Robert Orlowski on OncoDaily.

cancer Chezi Ganzel Efrat Luttwak Evgeni Chubar Eyal Lebel Haematologica Hila Magen Ilana Pereg Inna Tzoran Irit Avivi Iuliana Vaxman Moshe E Gatt Moshe Mittelman Myeloma Paper of the Day Natan Melamed Netanel Horowitz Noa Lavi Noa Lowenton-Spier Nurit Horesh OncoDaily Oncology Revital Saban Robert Orlowski Svetlana Trestman Tamir Shragai Tsila Zuckerman Vladimir Vainstein Yaël C. Cohen